InnoCare Pharma signs a strategic research collaboration and licensing agreement with Eli Lilly that could be worth up to US$3.35 billion.
economy1 d ago
coda.news AI summary
- InnoCare Pharma is a Beijing-based cancer drug developer.
- It entered into a strategic research collaboration and licensing agreement with Eli Lilly.
- The potential value is up to US$3.35 billion.
- The announcement was made on Thursday.
SCMP BusinessRead original ↗